Estruturas impressas em 3D podem acelerar a terapia com células CAR-T

Pesquisadores desenvolveram géis impressos em 3D que mimetizam linfonodos para melhorar a produção de células CAR-T destinadas ao tratamento de câncer. A abordagem aumentou as taxas de sucesso e acelerou o crescimento celular em comparação com os métodos padrão. Isso pode ajudar a reduzir custos e expandir o acesso à terapia em todo o mundo.

O processo padrão para a criação de células CAR-T envolve a extração de células T de um paciente, sua modificação genética com um vírus para atacar o câncer e sua multiplicação ao longo de várias semanas. Isso pode custar mais de 280 mil libras por rodada e frequentemente leva até um mês, limitando a disponibilidade, especialmente em países de baixa renda.

Artigos relacionados

Illustration of a German woman achieving complete remission from three autoimmune diseases via groundbreaking CAR-T therapy, symbolizing hope and medical triumph.
Imagem gerada por IA

CAR-T therapy achieves complete remission of three autoimmune diseases in German woman

Reportado por IA Imagem gerada por IA

A 47-year-old woman bedridden with autoimmune hemolytic anemia, immune thrombocytopenia, and antiphospholipid syndrome has achieved complete remission after CAR-T cell therapy at University Hospital Erlangen in Germany. Treated by Fabian Müller after nine failed therapies, she recovered rapidly and remains healthy over a year later without medication—the first simultaneous treatment of multiple autoimmune diseases with this method.

Researchers have found that making cancer cells stiffer can enhance the effectiveness of car t-cell therapy against aggressive tumors. In experiments with mice, the approach led to complete tumor disappearance in some cases. The findings were presented recently at a conference in London.

Reportado por IA

A small study has found that CAR-T cell therapy may offer a new way to manage HIV over the long term. The approach, already used to treat certain cancers, involves engineering a patient’s own immune cells.

Caribou Biosciences discussed progress on its off-the-shelf CAR-T therapies during a presentation at the Bank of America Global Healthcare Conference on May 13. Chief executive Rachel Haurwitz highlighted Phase I data for two programs that target lymphoma and multiple myeloma.

Reportado por IA

Scientists at McMaster University and the Hospital for Sick Children in Canada have discovered that oligodendrocytes, cells typically supporting nerve function, aid the growth of glioblastoma by sending signals to tumor cells. Blocking this communication slowed tumor progression in lab models. The findings suggest an existing HIV drug, Maraviroc, could be repurposed for treatment.

Este site usa cookies

Usamos cookies para análise para melhorar nosso site. Leia nossa política de privacidade para mais informações.
Recusar